Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > New Press Release - Spectral Medical Provides January Tigris Trial Update

<< Previous

Bullboard Posts

Next >>

Comment by PezDalatoYouon Jan 30, 2024 11:08am

171 Views

Post# 35852599

RE:RE:New Press Release - Spectral Medical Provides January Tigris Trial Update

I noticed that as well. They sure like to keep everyone guessing. So, why is this info missing from this particular PR?

1. They forgot to put it in.
2. After so many PRs with it in, they felt it wasn't necessary anymore.
3. They aren't 'exceeding expectations' anymore and can't put it in and they don't want to share the revised state.
4. ?

I'm guessing #2. I highly doubt that we would swing from exceeding to 'meeting' or 'not meeting' with the addition of 3 patients.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide